FY2024 EPS Estimates for Nuvectis Pharma Raised by Analyst

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Stock analysts at Roth Capital boosted their FY2024 EPS estimates for Nuvectis Pharma in a research report issued on Tuesday, November 5th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings per share of ($1.00) for the year, up from their previous forecast of ($1.02). The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.05) per share. Roth Capital also issued estimates for Nuvectis Pharma’s Q4 2024 earnings at ($0.25) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.94) EPS and FY2027 earnings at $1.64 EPS.

Separately, HC Wainwright reiterated a “buy” rating and issued a $21.00 target price on shares of Nuvectis Pharma in a report on Tuesday, August 6th.

Nuvectis Pharma Stock Up 2.3 %

Shares of NASDAQ NVCT opened at $8.34 on Thursday. The stock’s fifty day simple moving average is $6.84 and its 200 day simple moving average is $6.69. The stock has a market capitalization of $155.54 million, a price-to-earnings ratio of -6.47 and a beta of 0.41. Nuvectis Pharma has a 52-week low of $5.85 and a 52-week high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same period last year, the business posted ($0.37) earnings per share.

Hedge Funds Weigh In On Nuvectis Pharma

Several institutional investors and hedge funds have recently bought and sold shares of NVCT. GSA Capital Partners LLP increased its position in Nuvectis Pharma by 3.7% in the 3rd quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock worth $315,000 after purchasing an additional 1,790 shares during the last quarter. Nations Financial Group Inc. IA ADV bought a new stake in shares of Nuvectis Pharma during the 3rd quarter worth about $63,000. Iridian Asset Management LLC CT acquired a new position in shares of Nuvectis Pharma during the 3rd quarter valued at about $348,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Nuvectis Pharma in the 2nd quarter worth approximately $58,000. Finally, Renaissance Technologies LLC boosted its position in Nuvectis Pharma by 20.7% during the second quarter. Renaissance Technologies LLC now owns 74,500 shares of the company’s stock worth $472,000 after purchasing an additional 12,800 shares during the period. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.